Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women who have been newly diagnosed with post-menopausal osteoporosis, requiring treatment;~* naive to bisphosphonate treatment,or had bisphosphonate treatment for a maximum of 3 months, at least 5 years before screening.~Exclusion Criteria:~* patients on hormone replacement therapy (HRT) within the last 3 months;~* patients on other osteoporosis medication within the last 3 months;~* sCTX below lower limit, or above 3 times the upper limit, of normal premenopausal level;~* hypersensitivity to any component of ibandronate;~* contraindication for calcium or vitamin D therapy;~* history of major gastrointestinal upset;~* malignant disease diagnosed within the previous 10 years (except resected basal cell cancer).

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ibandronate (Type: EXPERIMENTAL): Participants received Ibandronate 150 mg tablet once-monthly along with a combination dietary supplement containing vitamin D 200 international units (IU) and elemental calcium 500 mg twice daily with meals for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a matching placebo tablet to Ibandronate once-monthly along with a combination dietary supplement containing vitamin D 200 IU and elemental calcium 500 mg twice daily with meals for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).